Literature DB >> 24914062

Relationships between sex, early valve surgery and mortality in patients with left-sided infective endocarditis analysed in a population-based cohort study.

Elodie Curlier1, Bruno Hoen1, François Alla2, Christine Selton-Suty3, Lucile Schubel4, Thanh Doco-Lecompte5, Laetitia Minary2, Marie-Line Erpelding2, Xavier Duval6, Catherine Chirouze7.   

Abstract

OBJECTIVE: Whether sex-related differences in the prognosis of infective endocarditis (IE) are due to differences in disease severity or comorbid patterns, physiological specificities or a treatment indication bias is unclear. We conducted an analysis of the pooled database of two population-based cohorts of IE to reassess the relationships between sex, early valve surgery (EVS) and outcome in patients with IE.
METHODS: Demographic and baseline characteristics, complications and outcome were compared in men and women with Duke-definite left-sided IE. A propensity model for EVS was constructed using multivariate logistic regression. Factors associated with 1-year mortality were identified using multivariate Cox models adjusted for EVS factors.
RESULTS: The study population included 466 (75%) men and 154 (25%) women. Compared with men, women were older (p=0.005), were more often on haemodialysis (p=0.04), more often had a mitral valve IE (50.0% vs 35.8%, p=0.02), less often developed a septic shock (p=0.05), less often underwent EVS (p=0.001) yet had comparable inhospital mortality rates (20.1% vs 20.0%, p=0.96) and similar 1-year survival probability (logrank p=0.68). Female sex was neither associated with EVS (OR 0.76 (95% CI 0.49 to 1.16)) nor mortality (HR 1.17 (95% CI 0.80 to 1.69)). However EVS was associated with an increased risk of death in women in the early postoperative period (HR 8.72 (95% CI 3.42 to 22.24), p=<0.0001).
CONCLUSIONS: Women underwent EVS less often than men. However female sex was independently associated with neither EVS nor 1-year mortality. The reasons for a higher risk of early postoperative mortality in women must still be elucidated. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Year:  2014        PMID: 24914062     DOI: 10.1136/heartjnl-2013-304916

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Sex Differences in Characteristics of Patients with Infective Endocarditis: A Multicenter Study.

Authors:  Ruchi Bhandari; Shabnam Tiwari; Talia Alexander; Frank H Annie; Umar Kaleem; Affan Irfan; Sudarshan Balla; R Constance Wiener; Chris Cook; Aravinda Nanjundappa; Mark Bates; Ellen Thompson; Gordon S Smith; Judith Feinberg; Melanie A Fisher
Journal:  J Clin Med       Date:  2022-06-18       Impact factor: 4.964

2.  Infective endocarditis in the Pacific: clinical characteristics, treatment and long-term outcomes.

Authors:  Mariana Mirabel; Romain André; Paul Barsoum Mikhaïl; Hester Colboc; Flore Lacassin; Baptiste Noël; Jacques Robert; Marie Nadra; Corinne Braunstein; Shirley Gervolino; Eloi Marijon; Bernard Iung; Xavier Jouven
Journal:  Open Heart       Date:  2015-04-30

3.  Native aortic versus mitral valve infective endocarditis: a nationwide registry study.

Authors:  Abel Van Vlasselaer; Magnus Rasmussen; Johan Nilsson; Lars Olaison; Sigurdur Ragnarsson
Journal:  Open Heart       Date:  2019-02-27

4.  Sex-Specific Risk Factors for Short- and Long-Term Outcomes after Surgery in Patients with Infective Endocarditis.

Authors:  Christine Friedrich; Mohamed Salem; Thomas Puehler; Bernd Panholzer; Lea Herbers; Julia Reimers; Lars Hummitzsch; Jochen Cremer; Assad Haneya
Journal:  J Clin Med       Date:  2022-03-28       Impact factor: 4.241

5.  Combined efficacy of C-reactive protein and red blood cell distribution width in prognosis of patients with culture-negative infective endocarditis.

Authors:  Xue-Biao Wei; Yuan-Hui Liu; Peng-Cheng He; Ying-Ling Zhou; Ning Tan; Ji-Yan Chen; Dan-Qing Yu
Journal:  Oncotarget       Date:  2017-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.